Abstract
The article presents the analysis of literature data on the pathogenesis, course and pharmacotherapy in pregnancy during respiratory allergic diseases. The article also considers the systematized ARIA recommendations (Updated 2020) on the diagnosis and pharmacotherapy of allergic rhinitis (AR) in pregnancy, differential diagnosis concerning nasal breathing disorders of atopic and non-atopic etiology during gestation, and the developed therapeutic methods for the patient management (in particular, pregnant women) with an allergic phenotype (a combination of asthma with allergic rhinitis and/or atopic dermatitis). The association between the uncontrolled course of allergic rhinitis in pregnant women and the risk of the bronchial asthma onset has been proven. Of utmost importance, for improving perinatal outcomes is the optimization of therapy and symptom control of allergic diseases during pregnancy in the interdisciplinary practice of an obstetrician-gynecologist and allergist/immunologist. AR in pregnancy should be differentiated from the most common form of nasal breathing disorders in pregnant women — vasomotor rhinitis. Severe uncontrolled vasomotor rhinitis in pregnant women, as an individual nosological form, can worsen the existing AR and bronchial asthma course. The authors present a mathod for the AR step therapy based on pharmacological characteristics and safety profile of drugs in pregnancy. KEYWORDS: allergic rhinitis, bronchial asthma, pregnancy, vasomotor rhinitis of pregnant women, pharmacotherapy, obstetric complications. FOR CITATION: Paschenko A.A., Dobrokhotova Yu.E., Fomina D.S., Pashchenko M.G. Uncontrolled course of respiratory allergic diseases in pregnant women. Russian Journal of Woman and Child Health. 2022;5(2):122–128 (in Russ.). DOI: 10.32364/2618-8430- 2022-5-2-122-128.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
